NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) — Attention Origin Materials, Inc. (“Origin”) (NASDAQ: ORGN) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between February 23, 2023 and August 9, 2023.
If you suffered a loss on your investment in Origin, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/origin-class-action-submission-form/?prid=47957&wire=3
ABOUT THE ACTION: The class action against Origin includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Origin would not be able to meet its previously announced timeline for the construction of the Origin 2 plant; (2) demand for paraxylene (“PX”) had dropped such that it would not be the production focus of Origin 2; (3) Origin could not construct Origin 2 at its previously disclosed cost; (4) Origin could not construct Origin 2 at the scale it had previously identified; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and lacked a reasonable basis.
DEADLINE: October 24, 2023
Aggrieved Origin investors only have until October 24, 2023 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
- Aviation Analytics Market Size Will Attain USD 8 Billion by 2030 Growing at 9.8% CAGR – Exclusive Report by Zion Market Research - September 27, 2023
- Radio Transmitter Market Surges to USD 387.6 Million by 2032, Propelled by a Remarkable CAGR of 1.2% | Market.us - September 27, 2023
- Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies - September 27, 2023
